Revvity Inc (RVTY)

Currency in USD
98.49
+2.54(+2.65%)
Closed·
98.490.00(0.00%)
·
RVTY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
95.8298.57
52 wk Range
81.36120.39
Key Statistics
Prev. Close
95.95
Open
96.59
Day's Range
95.82-98.57
52 wk Range
81.36-120.39
Volume
1.16M
Average Volume (3m)
1.35M
1-Year Change
-11.85%
Book Value / Share
63.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RVTY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
119.56
Upside
+21.40%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Revvity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Revvity Inc Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revvity Inc Earnings Call Summary for Q4/2025

  • Revvity Q4 2025 reported adjusted EPS of $1.70 (vs $1.55 forecast) and revenue of $772M (vs $758.53M expected), yet stock fell 7.89% pre-market to $100.22
  • Q4 showed 4% organic revenue growth with 29.7% adjusted operating margin; full-year 2025 delivered $2.86B revenue (3% organic growth) and $5.06 adjusted EPS
  • Company launched new AI services including Synthetica platform and acquired ACD/Labs while repurchasing over $800M in shares during 2025
  • 2026 guidance projects revenue of $2.96-2.99B (2-3% organic growth) and adjusted EPS of $5.35-5.45, with CEO expressing optimism about market recovery
  • Challenges remain in academic/government markets, biotech funding environment, and potential macroeconomic pressures affecting key market spending
Last Updated: 02/02/2026, 10:20 PM
Read Full Transcript

Compare RVTY to Peers and Sector

Metrics to compare
RVTY
Peers
Sector
Relationship
P/E Ratio
45.9x28.6x−0.5x
PEG Ratio
−7.940.680.00
Price/Book
1.5x3.1x2.6x
Price / LTM Sales
3.9x3.1x3.2x
Upside (Analyst Target)
20.8%0.0%51.3%
Fair Value Upside
Unlock3.3%8.9%Unlock

Analyst Ratings

11 Buy
8 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 119.56
(+21.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Hold110.00+11.69%110.00MaintainFeb 03, 2026
TD Cowen
Buy124.00+25.90%120.00MaintainFeb 03, 2026
KeyBanc
Buy125.00+26.92%-MaintainFeb 03, 2026
Wells Fargo
Hold110.00+11.69%107.00MaintainFeb 03, 2026
Barclays
Buy118.00+19.81%115.00MaintainFeb 03, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.06%
Dividend Yield
0.28%
Industry Median 1.34%
Annualized payout
0.28
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 02, 2026
EPS / Forecast
1.70 / 1.55
Revenue / Forecast
772.06M / 758.53M
EPS Revisions
Last 90 days

RVTY Income Statement

People Also Watch

841.27
GEV
-0.09%
319.04
WAT
+2.21%
223.18
CAH
-1.40%
108.74
DECK
-1.02%
72.21
BSX
-2.22%

FAQ

What Is the Revvity (RVTY) Stock Price Today?

The Revvity stock price today is 98.49 USD.

What Stock Exchange Does Revvity Trade On?

Revvity is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Revvity?

The stock symbol for Revvity is "RVTY."

Does Revvity Pay Dividends? What’s The Current Dividend Yield?

The Revvity dividend yield is 0.28%.

What Is the Revvity Market Cap?

As of today, Revvity market cap is 11.00B USD.

What Is Revvity's Earnings Per Share (TTM)?

The Revvity EPS (TTM) is 2.06.

When Is the Next Revvity Earnings Date?

Revvity will release its next earnings report on May 04, 2026.

From a Technical Analysis Perspective, Is RVTY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Revvity Stock Split?

Revvity has split 4 times.

How Many Employees Does Revvity Have?

Revvity has 11000 employees.

What is the current trading status of Revvity (RVTY)?

As of Mar 05, 2026, Revvity (RVTY) is trading at a price of 98.49 USD, with a previous close of 95.95 USD. The stock has fluctuated within a day range of 95.82 USD to 98.57 USD, while its 52-week range spans from 81.36 USD to 120.39 USD.

What Is Revvity (RVTY) Price Target According to Analysts?

The average 12-month price target for Revvity is 119.56 USD, with a high estimate of 140 USD and a low estimate of 105 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21.40% Upside potential.

What Is the RVTY Premarket Price?

RVTY's last pre-market stock price is 95.44 USD. The pre-market share volume is 124.00, and the stock has decreased by -0.51, or -0.53%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.